Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenosine monophosphate deaminase 2 (AMPD2)
- Target
- AMPD2
- Molecular classification
- Enzyme
01
Overview
Adenosine monophosphate deaminase 2 (AMPD2) is an enzyme that catalyzes the deamination of AMP to IMP, a critical step of the purine nucleotide cycle essential for regulating cellular energy levels; in humans, AMPD2 is predominantly expressed in the liver, brain, and kidneys, where it facilitates ATP turnover and energy homeostasis. AMPD2 is encoded by the AMPD2 gene on chromosome 1p21-p34, and dysfunction caused by recessive mutations is linked to severe neurological and metabolic diseases such as pontocerebellar hypoplasia type 9 and spastic paraplegia 63, as well as kidney and lipid disorders. While direct pharmacological modulators are currently not reported, AMPD2 and its variants are considered significant enzymes in metabolism and potential diagnostic markers for relevant inherited metabolic disorders.
- Other names
- AMP deaminase 2AMPD2SPG63AMP deaminase isoform LAMPD isoform LPCH9adenosine monophosphate deaminase 2 (isoform L)
02
Mechanism of action
Not directly characterized for drug targeting. AMPD2 enzymatic activity involves the deamination of AMP to IMP in the purine nucleotide cycle. Any theoretical drug would likely inhibit or enhance this enzymatic function.
03
Biological functions
Purine nucleotide metabolismCellular energy managementRegulation of AMP to IMP conversionEnergy homeostasisMetabolic regulation (especially in liver, brain, and kidney)
04
Disease associations
Neurodegenerative disease (e.g., pontocerebellar hypoplasia type 9)Neuromuscular disorder (e.g., spastic paraplegia 63)Metabolic disorders (e.g., nephrotic syndrome, hypercholesterolemia)
05
Safety considerations
Loss-of-function mutations cause severe neurological or metabolic dysfunction (e.g., neurodegeneration, kidney pathology)As AMPD2 is crucial for energy homeostasis, targeted inhibition may risk systemic metabolic imbalance
06
Interacting drugs
None specifically reported in provided sources or major databases as direct AMPD2 modulators
07
Biomarkers
AMPD2 genetic mutations (SNPs, deletions, truncations) as diagnostic markers for pontocerebellar hypoplasia type 9 and spastic paraplegia 63Metabolic intermediates of purine metabolism (e.g., AMP, IMP) for functional assessmentAdditional metabolic enzymes (AMPD1, AMPD3, ADSL, PKM, LDH) may serve as contextual biomarkers in related energy metabolism disorders
Beyond the preview
Go deeper on Adenosine monophosphate deaminase 2 (AMPD2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adenosine monophosphate deaminase 2 (AMPD2).